

# Anders Mellemsgaard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7043302/publications.pdf>

Version: 2024-02-01

28  
papers

1,291  
citations

687363

13  
h-index

580821

25  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2068  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study. <i>Scientific Reports</i> , 2021, 11, 16892.	3.3	4
2	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta Oncologica</i> , 2021, 60, 1565-1571.	1.8	2
3	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35.	2.0	42
4	Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. <i>Thorax</i> , 2018, 73, 530-537.	5.6	35
5	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report. <i>Frontiers in Immunology</i> , 2018, 9, 2145.	4.8	37
6	The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2017, 69, 444-453.	2.0	31
7	Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study. <i>Acta Oncologica</i> , 2017, 56, 335-341.	1.8	7
8	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. <i>Future Oncology</i> , 2017, 13, 1159-1171.	2.4	17
9	The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. <i>Histopathology</i> , 2017, 70, 889-895.	2.9	3
10	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000102.	4.5	9
11	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	3.6	30
12	Retrospective analysis to compare the efficacy of oral (O) vs. intravenous (IV) etoposide given in combination with carboplatin for small cell lung cancer (SCLC), extensive disease (ED).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20020-e20020.	1.6	1
13	Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2610-TPS2610.	1.6	6
14	Programmed cell death receptor ligand 1 (PD-L1) expression: Epidermal growth factor receptor (EGFR) and Kirsten RAS (KRAS) mutations in second-line therapy (2L) non-small cell lung cancer (NSCLC) patients—A Danish cohort study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20523-e20523.	1.6	0
15	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. <i>Biologics: Targets and Therapy</i> , 2015, 9, 47.	3.2	7
16	Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 317-326.	2.8	58
17	Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold intensity-modulated radiotherapy for locally advanced lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 55-63.	0.6	10
18	Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. <i>Lung Cancer</i> , 2015, 90, 267-273.	2.0	26

#	ARTICLE	IF	CITATIONS
19	The prevalence of <scp>EGFR</scp> mutations in non-small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , 2015, 123, 108-115.	2.0	55
20	Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19021-e19021.	1.6	2
21	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230.	2.0	41
22	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 143-155.	10.7	823
23	High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. <i>Modern Pathology</i> , 2014, 27, 1590-1598.	5.5	18
24	Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8100-8100.	1.6	2
25	Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8103-8103.	1.6	6
26	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8011-LBA8011.	1.6	19
27	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8011-LBA8011.	1.6	0
28	Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8084-8084.	1.6	0